6.6.8. guidelines first-line treatment hormone-sensitive metastatic disease*. recommendationsstrength ratingoffer immediate systemic treatment androgen deprivation therapy (adt) palliate symptoms reduce risk potentially serious sequelae advanced disease (spinal cord compression, pathological fractures, ureteral obstruction) m1 symptomatic patients.strongoffer short-term administration older generation androgen receptor (ar) antagonist m1 patients starting lhrh agonist reduce risk ‘flare-up’ phenomenon.weakat start adt offer luteinising hormone-releasing hormone (lhrh) antagonists orchiectomy patients impending clinical complications spinal cord compression bladder outlet obstruction.strongdo offer ar antagonist monotherapy patients m1 disease.strongdo offer adt monotherapy patients whose first presentation m1 disease contra-indications combination therapy sufficient life expectancy benefit combination therapy (≥ 1 year) willing accept increased risk side effects.strongoffer adt combined abiraterone acetate plus prednisone apalutamide enzalutamide patients m1 disease fit regimen.strongoffer docetaxel combination adt plus abiraterone darolutamide patients m1 disease fit docetaxel.strongoffer adt combined prostate radiotherapy (using doses equivalent 72 gy 2 gy fractions) patients whose first presentation m1 disease low volume disease chaarted criteria.strongdo offer adt combined surgery m1 patients outside clinical trials.strongonly offer metastasis-directed therapy m1 patients within clinical trial setting well-designed prospective cohort study.strong *all following statements based metastatic disease defined bone scintigraphy ct scan/mri.